The Use of Fidaxomicin for Treatment of Relapsed Clostridium difficile Infections in Patients with Cancer. Issue 11 (28th August 2014)

• Record Type: Journal Article
• Authors: Esmaily‐Fard, Amin; Tverdek, Frank P.; Crowther, David M.; Ghantoji, Shashank S.; Adachi, Javier A.; Chemaly, Roy F.
• Is Part Of: Pharmacotherapy. Volume 34:Issue 11(2014)
• Page Start: 1220
• Page End: 1225
• Publication Date: 2014-08-28
• Subjects: Chemotherapy -- Periodicals; Pharmacology -- Periodicals; Drug Therapy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1002/phar.1479
• Languages: English
• ISSNs: 0277-0008

Abstract

<abstract abstract-type="main" id="phar1479-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="phar1479-sec-0001" sec-type="section"> <title>Objectives</title> <p>To report our experience with the use of fidaxomicin (FDX), an oral macrocyclic antibiotic, in cancer patients with <italic>Clostridium difficile</italic> infection (CDI).</p> </sec> <sec id="phar1479-sec-0002" sec-type="section"> <title>Methods</title> <p>A single‐center retrospective case series was conducted at The University of Texas MD Anderson Cancer Center. Patients with CDI treated with FDX from May 2011 to January 2013 were identified via the pharmacy database. Clinical response and recurrence after FDX initiation were evaluated.</p> </sec> <sec id="phar1479-sec-0003" sec-type="section"> <title>Results</title> <p>Twenty‐two patients were included, most of whom were male (55%) with a mean age of 58 years (range: 20–83 yrs). The most common underlying malignancies were nine patients with lymphoma (41%), seven with leukemia (32%), and six with solid tumors (27%). Indications for FDX included recurrent CDI in 16 patients (72%) and failure of both metronidazole and oral vancomycin in 6 patients (28%). Nineteen patients (86%) were on concomitant antimicrobials during CDI treatment. Clinical response to FDX was 91%, and overall sustained clinical response was 82%. FDX was well tolerated with no major adverse events that were FDX related or discontinuations due to drug‐related adverse events.</p> </sec> <sec id="phar1479-sec-0004" sec-type="section"> <title>Conclusion</title> <p>In cancer patients, FDX is effective treatment for the first episode of CDI after failure of standard therapies and treatment of recurrent CDI. This was interesting given the large number of high‐risk patients who continued to receive concomitant antimicrobial therapy, which is common in this immunocompromised patient population.</p> </sec> </abstract>